Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats

Cisplatin (cis-diamminedicloroplatinum) is an antineoplastic drug used in the treatment of a variety of cancers, especially head-and-neck cancer. Its ototoxicity, however, has been noted as a common side-effect which limits its use and causes significant morbidity. AIM: to assess distortion-product otoacoustic emissions (DPOAE) and brainstem evoked response audiometry (BERA) sensitivity to detect secondary ototoxicity caused by different doses and means of administration of cisplatin in rats. STUDY DESIGN: Experimental. MATERIAL AND METHODS: Male Wistar rats were intraperitoneally (i.p.) injected with 24 mg/kg cisplatin, divided into three equal doses (8mg/kg) or a single i.p. injection of 16 mg/kg. The animals were evaluated by distortion product otoacoustic emission (DPOAE) or brainstem evoked response audiometry (BERA) on the 3rd and 4th days after the cisplatin injection. RESULTS: Treatment with cisplatin 24 mg/kg resulted in significant DPOAE decrease and it raised the BERA electrophysiological threshold. The 16mg/kg dose could not significantly reduce the DPOAE amplitude, but it raised the animals' hearing thresholds - detected by the BERA. CONCLUSION: In rats, BERA was more sensitivity than DPOAE at detecting cisplatin-induced ototoxicity in rats considering different doses and means of administration.

Bibliographic Details

Main Authors:	Freitas,Marcos Rabelo de, Silva,Viviane Carvalho da, Brito,Gerly Anne de Castro, Carvalho Junior,José Valdir de, Gomes Junior,Raimundo Martins, Ribeiro,Ronaldo de Albuquerque
Format:	Digital revista
Language:	English
Published:	Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. 2009
Online Access:	http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000400002
Tags:	Add Tag No Tags, Be the first to tag this record!